PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) will present new preclinical data on DNA-based protein therapies for hemophilia at the World Federation of Hemophilia World Congress in Kuala Lumpur on Wednesday, April 22.
The company is scheduled to deliver an oral presentation examining its DNA-encoded protein (DPROT) technology, which demonstrated in vivo production of functional Factor VIII in a mouse model.
A separate poster presentation will detail results from INOVIO’s non-viral DNA medicine platform, which produced therapeutic levels of Factor VIII protein and corrected bleeding symptoms in hemophilia A mice.
The oral presentation is scheduled for 9:45 a.m. MYT, followed by the poster presentation at 10:45 a.m. MYT.
Hemophilia A is a genetic bleeding disorder caused by a deficiency in Factor VIII, a protein necessary for blood clotting, and is commonly treated with protein replacement therapies.
INOVIO’s research focuses on enabling the body to produce therapeutic proteins internally using DNA-based delivery, an approach that differs from traditional infusion-based treatments.
The company’s platform uses non-viral vectors designed to express proteins within the body, with the goal of improving treatment durability and reducing the need for repeated dosing.
Abstracts from both presentations will be made available on INOVIO’s website following the conference.
INOVIO is a biotechnology company developing DNA medicines targeting HPV-associated diseases, cancer, and infectious diseases, in addition to rare disease applications such as hemophilia.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.